Recurrence patterns in patients with advanced non-small cell lung cancer who have received epidermal growth factor receptor tyrosine kinase inhibitors
Keywords:
NSCLC, EGFR-TKIs, recurrence patternsAbstract
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erotinib, have shown efficacy in patients with advanced non-small cell lung cancer (NSCLC). However, information on initial failure sites in patients treated with EGFR-TKIs is limited. This retrospective study was undertaken to investigate the recurrence patterns in these patients. We retrospectively reviewed the initial failure sites of 52 EGFR-TKI treated patients with stage III/IV NSCLC and sensitizing EGFR mutation in Shandong Provincial Hospital. The median progression free survival (PFS) was evaluated by the Kaplan-Meier method. The median age of the 52 patients treated with EGFR-TKIs was 57 years (range, 37-80 years). The median PFS was 8 months. The most frequent initial site of progression was the lung (38.46%), which was followed by the central nervous system (CNS) (30.77%), bone (17.31%) and other places (liver, adrenal, skin, etc.). The lung and CNS were two of the most common recurrence sites in EGFR-TKI treated patients with stage IIIB/IV NSCLC harboring somatic EGFR mutation. We should pay more attention to the response of the lung and brain for early detection of disease recurrence.
Downloads
Published
Issue
Section
License
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.